GB0609530D0 - Combination - Google Patents

Combination

Info

Publication number
GB0609530D0
GB0609530D0 GBGB0609530.1A GB0609530A GB0609530D0 GB 0609530 D0 GB0609530 D0 GB 0609530D0 GB 0609530 A GB0609530 A GB 0609530A GB 0609530 D0 GB0609530 D0 GB 0609530D0
Authority
GB
United Kingdom
Prior art keywords
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0609530.1A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Priority to GBGB0609530.1A priority Critical patent/GB0609530D0/en
Publication of GB0609530D0 publication Critical patent/GB0609530D0/en
Priority to PCT/GB2007/001780 priority patent/WO2007132228A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0609530.1A 2006-05-12 2006-05-12 Combination Ceased GB0609530D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0609530.1A GB0609530D0 (en) 2006-05-12 2006-05-12 Combination
PCT/GB2007/001780 WO2007132228A1 (en) 2006-05-12 2007-05-14 Combination of cndac with a 2-substituted-4-heter0aryl-pyrimidine amine and use thereof in the treatment of a proliferative disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0609530.1A GB0609530D0 (en) 2006-05-12 2006-05-12 Combination

Publications (1)

Publication Number Publication Date
GB0609530D0 true GB0609530D0 (en) 2006-06-21

Family

ID=36637455

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0609530.1A Ceased GB0609530D0 (en) 2006-05-12 2006-05-12 Combination

Country Status (2)

Country Link
GB (1) GB0609530D0 (en)
WO (1) WO2007132228A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2148676T3 (en) * 2007-04-25 2016-12-30 Use of sapacitabine to treat proliferative disease
US7863255B2 (en) * 2008-04-29 2011-01-04 Taiho Pharmaceutical Co., Ltd. Methods of administering antitumor agent comprising deoxycytidine derivative
ES2401951T3 (en) * 2008-06-09 2013-04-25 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
CN101638808B (en) * 2008-07-31 2012-10-17 复旦大学 Method for screening enhanced anti-tumor compounds
WO2010074724A1 (en) 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2012140436A1 (en) 2011-04-14 2012-10-18 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0328180D0 (en) * 2003-12-04 2004-01-07 Cyclacel Ltd Combination
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds

Also Published As

Publication number Publication date
WO2007132228A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
DE602007002700D1 (en) Interventionsfreies frac-system
EP2033216A4 (en) Electroadhesion
DE602007008085D1 (en) Dihydropyrazolopyrimidinonderivate
DE602007014031D1 (en) Luftreifensatz
DE602007002070D1 (en) 2-pyrazincarboxamidderivate
DE602007003855D1 (en) Isothermer reaktor
EP1983992A4 (en) 2-imino-benzimidazoles
DE602007001601D1 (en) Glasuntersuchung
ZA200903041B (en) Combination
DE602007006989D1 (en) Spiropiperidinderivate
GB0609530D0 (en) Combination
GB0609619D0 (en) Combination
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
DE602007011622D1 (en) Penem-prodrugs
EP2084019A4 (en) Paintscraper
EP2024567A4 (en) Earthen-wallpaper
EP2007388A4 (en) Opiopathies
DK1989111T3 (en) Satellitluftbremseapparat
EP1974618A4 (en) Innerwear
DE502007001126D1 (en) Eiten
GB0601584D0 (en) Cosyhold headscarf
AU3514P (en) ARCBENT Arctotis fastuosa
AU4914P (en) CalflatGL Calothamnus quadrifidus
GB0609531D0 (en) Combination
GB0609534D0 (en) Combination

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)